Abstract
Cell Surface Proteoglycans as Potential Targets for Immunotherapy in Women's Cancer
Highlights
Triple negative breast cancers constitute approximately 15-20% of all breast cancers and they are more aggressive compared to other phenotypes (e.g. Luminals A and B and Her2+)
We previously demonstrated that CSPG4 forms a complex with a metastasispromoting protein, NEDD9, in triple-negative breast cancer cells and regulates three-dimensional cancer growth [7,8]
There are several studies demonstrating the efficacy of targeting cell surface PGs for inhibiting growth and metastasis
Summary
Triple negative breast cancers constitute approximately 15-20% of all breast cancers and they are more aggressive compared to other phenotypes (e.g. Luminals A and B and Her2+). Triple negative breast cancers are harder to treat because of the absence of targets for hormonal therapies such as ER, PR, and Her2+. There are only limited neoadjuvant therapy regimens available that weaken or shrink triple negative breast cancer cells prior to surgical resection. One immediate requirement for the treatment of triplenegative breast cancer is to characterize and evaluate molecules that play important roles in promoting malignant phenotypes and to develop novel strategies that interfere with the functions of these proteins
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
